Why might CLOUT and DEFIANCE open the door to a new generation of data in DVT treatment?


Steven Abramowitz (Washington DC, USA) explains the significance of the CLOUT registry—the only registry capturing data on mechanical thrombectomy in deep venous thrombosis (DVT). CLOUT confirms excellent safety results and effectiveness of the ClotTriever system in real-world DVT patients. In a propensity-score matched analysis, comparing this modern mechanical thrombectomy and historical ATTRACT treatment outcomes, ClotTriever shows better thrombus extraction and improvement in 30-day Villalta score, suggesting potentially long-term implications for patient outcomes.  Apart from the CLOUT Registry, the ClotTriever system is part of the DEFIANCE Trial, a randomised controlled trial (RCT) evaluating its clinical outcome in DVT treatment. “The goal of DEFIANCE is to demonstrate that mechanical thrombectomy is superior to anticoagulation alone. The previous RCTs have all focused on catheter-delivered lytics and we know that the downside of lytics is bleeding, which was a significant outcome of the ATTRACT study—says Stephen Black (London, UK). “Trying to find something that avoids lytics is going to be really useful for this therapy”.

To learn more about clinical outcomes in the CLOUT Registry, the design of the DEFIANCE trial and benefits of the ClotTriever system, join the INARI Symposium at LINC 2023 (June 6–9, Leipzig, Germany) on June 7th (Wednesday) at 12:35–13:20 (Technical Forum).

This video was filmed by Inari Medical and is being sponsored for distribution in association with Vascular News, Interventional News, Venous News and CX Vascular. Biba Medical bears no responsibility for the assets used in the production of this video.


Please enter your comment!
Please enter your name here